US Pharma MarketingPfizer
Pfizer’s experimental 25-valent pneumococcal shot beats Prevnar 20; Relay Therapeutics charts $175M offering; Lilly to pay up to $202 million for non-viral DNA delivery specialist Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene…
💉 Pfizer’s experimental 25-valent pneumococcal shot beats Prevnar 20: The vaccine candidate, codenamed PF-07872412, produced higher geometric mean titers for serotype 3 than Pfizer’s approved 20-valent vaccine in a head-to-head Phase 2 trial in healthy ...
Source: Endpoints News